ENLIGHTEN-2

RecruitingPhase 3

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Obesity or Overweight, and Type 2 Diabetes

Lead sponsor

Eli Lilly and Company

Asset

Eloralintide

Subcutaneous · Amylin analog

Listed sites

159

Recruiting sites

115

Enrollment

1,035

estimated

Study population

Obesity / overweight, Type 2 diabetes

Key I/E criterion

•BMI ≥27

Primary endpoint

•Body weight, % change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07282600

Org study ID27741

Secondary ID2025-523658-15-00

Secondary IDJ3R-MC-YDAFEli Lilly and Company

Timeline

Milestones

Study first posted2025-12-15actual

Study start2025-12-15actual

Last update posted2026-05-22actual

Primary completion2028-01estimated (month precision)

Study completion2028-02estimated (month precision)

Assets

Investigational agents

Eloralintide

Study populations

Who this study enrolls

Obesity / overweightType 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Have type 2 diabetes

•Are on stable treatment for type 2 diabetes for at least 90 days prior to screening

•Have a BMI ≥ 27 kg/m2

•Have a stable body weight (<5% body weight change) for 90 days prior to screening

Exclusion criteria

•Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening)

•Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)

•Have type 1 diabetes

•Have taken any of the following antihyperglycemic medications within 90 days before screening:

–amylin analogs

–glucagon-like peptide-1 (GLP-1) receptor agonists

–glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GIP/GLP) receptor agonists, or

–insulin

•Have had within 90 days prior to screening:

–heart attack

–stroke

–coronary artery revascularization

–unstable angina, or

–hospitalization due to congestive heart failure

•Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure

•Have taken medications or alternative remedies intended for weight loss within 90 days of screening

Endpoints (17)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition

Patient-reported / QoL

Cardiometabolic biomarkers

Glycemic / diabetes

Safety / tolerability / PK

Renal / kidney

Other (unclassified)

Weight & body composition

4 endpoints

Primary/protocol endpoint

Percent Change from Baseline in Body Weight

Time frame:Baseline, Week 64

Body weight, % change

percent change from baseline, improvement

Secondary/protocol endpoint

Percent Change from Baseline in Total Body Fat Mass

Time frame:Baseline, Week 64

Total fat mass

percent change from baseline, improvement

Secondary/protocol endpoint

Change from Baseline in Waist Circumference

Time frame:Baseline, Week 64

Waist circumference, change

change from baseline, improvement

Secondary/protocol endpoint

Change from Baseline in Body Mass Index (BMI)

Time frame:Baseline, Week 64

BMI, change

change from baseline, improvement

Glycemic / diabetes

2 endpoints

Secondary/protocol endpoint

Change from Baseline in Hemoglobin A1c (HbA1c)

Time frame:Baseline, Week 64

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint/low confidence

Percent Change from Baseline in Fasting Insulin

Time frame:Baseline, Week 64

percent change from baseline, improvement

Renal / kidney

1 endpoint

Secondary/protocol endpoint

Change from Baseline in Estimated Glomerular Filtration Rate (eGFR)

Time frame:Baseline, Week 64

eGFR, change

change from baseline, improvement

LOINC 98979-8

Cardiometabolic biomarkers

3 endpoints

Secondary/protocol endpoint

Percent Change in Baseline in Triglycerides

Time frame:Baseline, Week 64

Triglycerides, change

percent change from baseline, improvement

LOINC 2571-8

Secondary/protocol endpoint

Change from Baseline in Systolic Blood Pressure

Time frame:Baseline, Week 64

Systolic BP, change

change from baseline, improvement

LOINC 8480-6

Secondary/protocol endpoint

Percent Change from Baseline in High Sensitivity C-Reactive Protein (hsCRP)

Time frame:Baseline, Week 64

hs-CRP, change

percent change from baseline, improvement

LOINC 30522-7

Patient-reported / QoL

4 endpoints

Secondary/protocol endpoint

Change from Baseline in Short Form-36 (SF-36 v2) Score

Time frame:Baseline, Week 64

SF-36 total

change from baseline, improvement

Secondary/protocol endpoint

Change from Baseline in EQ-5D-5L Score

Time frame:Baseline, Week 64

EQ-5D index

change from baseline, improvement

Secondary/protocol endpoint

Change from Baseline in Control of Eating Questionnaire (CoEQ) Score

Time frame:Baseline, Week 64

change from baseline, improvement

Secondary/protocol endpoint

Achievement of Improved Categorical Shift in Patient Global Impression of Severity (PGIS) Physical Function Weight

Time frame:Baseline, Week 64

PGI, change

threshold achievement, improvement

Safety / tolerability / PK

2 endpoints

Secondary/protocol endpoint

Pharmacokinetics (PK): Maximum Concentration at Steady State (Cmax,ss)

Time frame:Baseline through Week 64

Cmax

concentration, descriptive

Secondary/protocol endpoint

PK: Area Under the Concentration Versus Time Curve for One Dosing Interval at Steady State (AUC(0-ᴛ)ss)

Time frame:Baseline through Week 64

AUC₀–∞

concentration, descriptive

Other (unclassified)

1 endpoint

Secondary/protocol endpoint/low confidence

Change in Medication Use

Time frame:Baseline through Week 64

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.